Initial Results of PX-171-004, An Open-Label, Single-Arm, Phase II Study of Carfilzomib (CFZ) in Patients with Relapsed Myeloma (MM)

被引：0

作者：

Vu, Ravi ^{[1
]}

Wang, Michael ^{[2
]}

Orlowski, Robert ^{[2
]}

Stewart, A. Keith ^{[3
]}

Jagannath, Sundar ^{[4
]}

Kukreti, Vishal ^{[5
]}

Taylor, Jessica ^{[6
]}

Fuhrman, Diana ^{[6
]}

Cruickshank, Scott ^{[6
]}

Schwartz, Richard ^{[6
]}

Kunkel, Lori ^{[6
]}

Siegel, David ^{[7
]}

机构：

[1] Washington Univ, Sch Med, St Louis, MO USA

[2] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA

[3] Mayo Clin, Scottsdale, AZ USA

[4] St Vincents Comp Canc Ctr, New York, NY USA

[5] Princess Margaret Hosp, Toronto, ON M4X 1K9, Canada

[6] Proteolix Inc, Clin Operat, San Francisco, CA USA

[7] Hackensack Univ, Med Ctr, Hackensack, NJ USA

[8] MMRC, Norwalk, CT USA

来源：

BLOOD | 2008年 / 112卷 / 11期

关键词：

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：320 / 320

页数：1

共 50 条

[1] Phase II Study of Carfilzomib (CFZ) in Patients with Relapsed Myeloma (MM) (PX-171-004)
Vij, R.
Wang, M.
Orlowski, R.
Stewart, A. K.
Jagannath, S.
Kukreti, V.
Taylor, J.
Fuhrman, D.
Cruickshank, S.
Schwartz, R.
Kunkel, L.
Siegel, D.
[J]. CLINICAL LYMPHOMA & MYELOMA, 2009, 9 : S78 - S78
[2] Initial Results of PX-171-003, An Open-Label, Single-Arm, Phase II Study of Carfilzomib (CFZ) in Patients with Relapsed and Refractory Multiple Myeloma (MM)
Jagannath, Sundar
Vij, Ravi
Stewart, A. Keith
Somlo, George
Jakubowiak, Andrzej
Reiman, Tony
Trudel, Suzanne
Taylor, Jessica
Fuhrman, Diana
Cruickshank, Scott
Schwartz, Richard
Kunkel, Lori
Siegel, David
[J]. BLOOD, 2008, 112 (11) : 319 - 319
[3] Updated Results of Bortezomib-Naive Patients in PX-171-004, An Ongoing Open-Label, Phase II Study of Single-Agent Carfilzomib (CFZ) in Patients with Relapsed or Refractory Myeloma (MM)
Wang, Luhua
Siege, David
Kaufman, Jonathan L.
Stewart, A. Keith
Jakubowiak, Andrzej J.
Alsina, Melissa
Kukreti, Vishal
Bahlis, Nizar J.
McDonagh, Kevin T.
Belch, Andrew
Sebag, Michael
Gabrail, Nashat
Le, Mai H.
Bennett, Mark K.
Kunkel, Lori
Kauffman, Michael
Orlowski, Robert Z.
Vij, Ravi
[J]. BLOOD, 2009, 114 (22) : 127 - 128
[4] Phase II Study of Carfilzomib in Patients with Relapsed Myeloma (PX-171-004)
Vij, R.
Wang, M.
Orlowski, R.
Stewart, A. K.
Jagannath, S.
Kukreti, V.
Taylor, J.
Fuhrman, D.
Cruickshank, S.
Schwartz, R.
Kunkel, L.
Siegel, D.
[J]. CLINICAL LYMPHOMA & MYELOMA, 2009, 9 : S61 - S62
[5] PX-171-004, a multicenter phase II study of carfilzomib (CFZ) in patients with relapsed myeloma: An efficacy update
Vij, R.
Wang, M.
Orlowski, R.
Stewart, A. K.
Jagannath, S.
Kukreti, V.
Le, M. H.
Kunkel, L.
Siegel, D.
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
[6] PX-171-004, An Ongoing Open-Label, Phase II Study of Single-Agent Carfilzomib (CFZ) in Patients with Relapsed or Refractory Myeloma (MM); Updated Results From the Bortezomib-Treated Cohort
Siegel, David
Wang, Luhua
Orlowski, Robert Z.
Kaufman, Jonathan L.
Stewart, A. Keith
Kukreti, Vishal
Alsina, Melissa
Jakubowiak, Andrzej J.
Jagannath, Sundar
McDonagh, Kevin T.
Belch, Andrew
Bahlis, Nizar J.
Shustik, Chaim
Le, Mai H.
Kunkel, Lori
Bennett, Mark K.
Kauffman, Michael
Vij, Ravi
[J]. BLOOD, 2009, 114 (22) : 128 - 128
[7] An open-label, single-arm, phase 2 (PX-171-004) study of single-agent carfilzomib in bortezomib-naive patients with relapsed and/or refractory multiple myeloma
Vij, Ravi
Wang, Michael
Kaufman, Jonathan L.
Lonial, Sagar
Jakubowiak, Andrzej J.
Stewart, A. Keith
Kukreti, Vishal
Jagannath, Sundar
McDonagh, Kevin T.
Alsina, Melissa
Bahlis, Nizar J.
Reu, Frederic J.
Gabrail, Nashat Y.
Belch, Andrew
Matous, Jeffrey V.
Lee, Peter
Rosen, Peter
Sebag, Michael
Vesole, David H.
Kunkel, Lori A.
Wear, Sandra M.
Wong, Alvin F.
Orlowski, Robert Z.
Siegel, David S.
[J]. BLOOD, 2012, 119 (24) : 5661 - 5670
[8] SAFETY AND EFFICACY UPDATE OF PX-171-004, AN OPEN-LABEL PHASE II TRIAL OF CARFILZOMIB IN RELAPSED MULTIPLE MYELOMA
Siegel, D.
Wang, M.
Stewart, K.
Jakubowiak, A.
Jagannath, S.
McDonagh, K.
Kukreti, V.
Lonial, S.
Cruickshank, S.
Vij, R.
[J]. HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2009, 94 : 191 - 191
[9] UPDATED RESULTS FOR BORTEZOMIB (BTZ)-NAIVE PATIENTS (PTS) ENROLLED IN PX-171-004, AN ONGOING OPEN-LABEL, PHASE (PH) 2 STUDY OF CARFILZOMIB (CFZ), IN RELAPSED MULTIPLE MYELOMA (MM)
Kaufman, J. L.
Vesole, D. H.
Stewart, A.
Jakubowiak, A. J.
Jagannath, S.
Kukreti, V.
Mcdonagh, K. T.
Alsina, M.
Reu, F. J.
Orlowski, R. Z.
Kunkel, L.
Le, M. H.
Vij, R.
Wang, M.
[J]. ANNALS OF ONCOLOGY, 2011, 22 : 200 - 201
[10] Final results of PX-171-003-A0, part 1 of an open-label, single-arm, phase II study of carfilzomib (CFZ) in patients (pts) with relapsed and refractory multiple myeloma (MM)
Jagannath, S.
Vij, R.
Stewart, K.
Somlo, G.
Jakubowiak, A.
Trudel, S.
Schwartz, R.
Siegel, D.
Kunkel, L.
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)

← 1 2 3 4 5 →